ALTERED BIOLOGICAL ACTIVITY ASSOCIATED WITH C-TERMINAL MODIFICATIONS OF IL-7
Görgün G, van der Spek J, Cosenza L, Menevse A, Foss F. ALTERED BIOLOGICAL ACTIVITY ASSOCIATED WITH C-TERMINAL MODIFICATIONS OF IL-7. Cytokine 2002, 20: 17-22. PMID: 12441142, DOI: 10.1006/cyto.2002.1974.Peer-Reviewed Original ResearchConceptsLigand-binding inducesSrc-related kinasesLigand-receptor interactionsAltered biological activityTyrosine phosphorylationC-terminal modificationBiological activityB leukemia cellsJAK3 kinaseHydrophobic residuesGamma subunitsSelective biological activityCarboxyterminal regionAliphatic amino acidsIL-7Amino acidsKinaseIL-7 receptorBinding antagonistsSubunitsIL-7R.Epithelial tissuesGammac subunitsCell functionIL-7RDiphtheria fusion protein therapy of chemoresistant malignancies.
Frankel AE, Rossi P, Kuzel TM, Foss F. Diphtheria fusion protein therapy of chemoresistant malignancies. Current Cancer Drug Targets 2002, 2: 19-36. PMID: 12188918, DOI: 10.2174/1568009023333944.Peer-Reviewed Original ResearchConceptsTargeted toxinsFusion protein therapyDiphtheria toxinChemotherapy-refractory cancersSelective ligandsTumor-selective ligandsChemoresistant diseaseCombination chemotherapyNeoplastic stem cellsRefractory cancerChemoresistant malignancyGroup IPseudomonas exotoxinWidespread cancerTherapyCell functionCancer therapyAntiviral proteinProtein therapyCancerToxin